Anacor Pharma (ANAC) Misses Q1 Views
Tweet
Share
E-mailGet Alerts ANAC Hot Sheet
Join SI Premium – FREE
Anacor Pharmaceuticals, Inc. (Nasdaq: ANAC) reported Q1 loss of $0.49, $0.18 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $4.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
- Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
